Iovance Biotherapeutics Inc. (IOVA) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Iovance Biotherapeutics I...

    NASDAQ: IOVA · Real-Time Price · USD
    2.49
    0.29 (13.18%)
    At close: Sep 05, 2025, 3:59 PM
    2.49
    0.00%
    After-hours: Sep 05, 2025, 07:57 PM EDT

    Iovance Biotherapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 164.07M 1.19M n/a n/a
    Cost of Revenue
    		 124M 10.76M 21.14M 13.98M
    Gross Profit
    		 40.08M -9.57M -21.14M -13.98M
    Operating Income
    		 -395.28M -460.56M -398.88M -342.7M
    Interest Income
    		 20.27M 13.04M 2.98M 451K
    Pretax Income
    		 -375M -447.52M -395.89M -342.25M
    Net Income
    		 -372.18M -444.04M -395.89M -342.25M
    Selling & General & Admin
    		 153.02M 106.92M 104.1M 83.66M
    Research & Development
    		 282.34M 344.08M 294.78M 259.04M
    Other Expenses
    		 n/a n/a n/a n/a
    Operating Expenses
    		 435.35M 450.99M 398.88M 342.7M
    Interest Expense
    		 n/a n/a 2.98M n/a
    Selling & Marketing Expenses
    		 101.22M 79.22M n/a n/a
    Cost & Expenses
    		 559.35M 461.75M 398.88M 342.7M
    Income Tax Expense
    		 -2.83M -3.48M n/a n/a
    Shares Outstanding (Basic)
    		 289.88M 235.13M 159.26M 153.41M
    Shares Outstanding (Diluted)
    		 289.88M 235.13M 159.26M 153.41M
    EPS (Basic)
    		 -1.28 -1.89 -2.49 -2.23
    EPS (Diluted)
    		 -1.28 -1.89 -2.49 -2.23
    EBITDA
    		 -351.67M -427.43M -374.76M -328.27M
    EBIT
    		 -395.28M -460.56M -395.89M -342.25M
    Depreciation & Amortization
    		 43.61M 33.13M 21.14M 13.98M

    Add to Watchlist